PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

Inclusion Criteria:

* Age 18 to 75 years at the time of consent.
* Histologically or cytologically confirmed advanced or metastatic solid tumor that is refractory to, relapsed after, or intolerant of standard therapy, or for which no standard therapy exists.
* At least 1 measurable lesion per RECIST v1.1.
* Tumor antigen positivity documented by tissue biopsy and/or liquid biopsy using a protocol-specified assay; for dual-target cohort: co-expression of both antigens above threshold.
* ECOG performance status 0-1.
* Adequate organ function (hematologic, renal, hepatic) as defined by protocol labs.
* Ability to undergo lymphodepleting chemotherapy (if required) and receive IV cell infusion.
* Negative pregnancy test for individuals of childbearing potential; agreement to use effective contraception during study participation and for a protocol-defined period after infusion.
* Willingness to provide baseline blood samples and, when feasible, tumor biopsy for biomarker analyses.

Exclusion Criteria:

* Active, uncontrolled infection, including uncontrolled bacterial, fungal, or viral infection.
* Known uncontrolled HIV infection; active hepatitis B or hepatitis C with evidence of active replication (per local testing).
* Clinically significant cardiovascular disease (e.g., recent myocardial infarction, uncontrolled arrhythmia) that would increase risk from lymphodepletion or infusion.
* Active central nervous system (CNS) metastases that are symptomatic or require escalating steroids.

(Stable treated CNS disease may be allowed per protocol.)

* Current systemic immunosuppressive therapy (e.g., \>10 mg/day prednisone equivalent) within a protocol-defined window prior to lymphodepletion.
* Prior gene-modified cellular therapy within 3 months or any prior therapy that, in the investigator's judgment, would confound safety evaluation.
* Prior allogeneic hematopoietic stem cell transplant within 6 months, or active graft-versus-host disease.
* Pregnant or breastfeeding.
* Any condition that, in the investigator's opinion, would interfere with study participation, compliance, or interpretation of results.